4D Molecular Therapeutics (FDMT)
Engineers virus-based gene therapies for eye and lung diseases, led by a late-stage retinal candidate.
$14.84
vs last close−1.04 (−6.56%)
Something off on this page? Send us feedback.
Next report
Nov 10, 26
in 48 days
EPS estimate
−$1.04
Revenue estimate
$3.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.90−$0.86−$0.98−$1.01$0.43−$1.01−$1.04Pending
Estimate−$0.80−$0.84−$0.88−$1.02−$0.53−$0.97−$1.02−$1.04
Surprise−12.5%−2.4%−11.4%+1.0%+181.1%−4.1%−2.0%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.0K$14.0K$15.0K$90.0K$85.1M$3.0M$3.8MPending
Estimate$2.3M$537.5K$4.7K$30.9M$27.0M$2.6M$3.6M$3.5M
Surprise−100.0%−97.4%+221.2%−99.7%+215.2%+17.8%+4.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.91 | — | — |
| Sep 2027 | −$0.92 | — | — |
| Jun 2027 | −$1.11 | — | — |
| Mar 2027 | −$1.10 | — | — |
| Dec 2026 | −$1.04 | — | — |
| Nov 2026 | −$1.04 | — | — |
| Aug 2026 | −$1.02 | −$1.04 | −2.0% |
| May 2026 | −$0.97 | −$1.01 | −4.1% |
| Mar 2026 | −$0.53 | $0.43 | +181.1% |
| Nov 2025 | −$1.02 | −$1.01 | +1.0% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Sep 2020 | |||
| Dec 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.91 | — | — | $4.0M | — | — | — |
| Sep 2027 | −$0.92 | — | — | $4.0M | — | — | — |
| Jun 2027 | −$1.11 | — | — | $4.0M | — | — | — |
| Mar 2027 | −$1.10 | — | — | $4.0M | — | — | — |
| Dec 2026 | −$1.04 | — | — | $4.3M | — | — | — |
| Nov 10, 2026 | −$1.04 | — | — | $3.5M | — | — | — |
| Aug 13, 2026 | −$1.02 | −$1.04 | −2.0% | $3.6M | $3.8M | +4.4% | +4.6% |
| May 7, 2026 | −$0.97 | −$1.01 | −4.1% | $2.6M | $3.0M | +17.8% | +2.1% |
| Mar 18, 2026 | −$0.53 | $0.43 | +181.1% | $27.0M | $85.1M | +215.2% | −0.6% |
| Nov 10, 2025 | −$1.02 | −$1.01 | +1.0% | $30.9M | $90.0K | −99.7% | −3.1% |
| Aug 11, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 28, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 10, 2023 | |||||||
| Mar 15, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 28, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 25, 2021 | |||||||
| Sep 30, 2020 | |||||||
| Dec 16, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 |